Barriers and perceived limitations to early treatment of hemophilia
Open Access
- 1 May 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Blood Medicine
- Vol. 4, 49-56
- https://doi.org/10.2147/jbm.s43734
Abstract
Barriers and perceived limitations to early treatment of hemophilia Kapil Saxena Boston Hemophilia Center, Boston Children’s Hospital, Boston, MA, USA Early treatment of bleeds in hemophilia patients, both with and without inhibitors, has been shown to be of immense benefit in the overall clinical outcome. Despite the advantages of treating the bleeding episodes early, significant barriers and limitations remain. The aim of this review is to highlight the various barriers and perceived limitations to early therapy of bleeding episodes, especially in patients who have developed inhibitors to factor VIII. The peer-reviewed literature was searched for articles on hemophilia patients, with and without inhibitors, and early treatment, to identify the barriers to early treatment and potential impact on patient outcomes. The most important barrier is the educational barrier, which involves lack of awareness among patients regarding the signs of a bleed, as well as importance of early therapy. It is also common for parents or caregivers of school-age children to exhibit inconvenience and scheduling barriers. Distance to the treatment center can also play a role here. Some patients experience financial barriers related to cost of clotting factor products, insurance coverage, or insurance caps and out-of-pocket costs. Rarely, there can also be problems related to venous access or home infusion. Lastly, multiple psychosocial barriers can prevent adherence to treatment regimens. Identification and addressing these individual barriers will result in improved compliance rates, prevent joint damage, be more cost-effective, and lead to better overall health of these patients. Keywords: hemophilia A, hemophilia B, inhibitors, outcomes, quality of life, cost of careKeywords
This publication has 57 references indexed in Scilit:
- Secondary prophylaxis with recombinant activated factor VII improves health‐related quality of life of haemophilia patients with inhibitorsHaemophilia, 2008
- Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modelingCurrent Medical Research and Opinion, 2008
- Medical Costs and Resource Utilization for Hemophilia Patients With and Without HIV or HCV InfectionJournal of Managed Care Pharmacy, 2007
- Orthopaedic issues in sports for persons with haemophiliaHaemophilia, 2007
- Inhibitor EconomicsSeminars in Hematology, 2006
- Compliance with treatment and understanding of own disease in patients with severe and moderate haemophiliaHaemophilia, 2006
- Practice patterns in haemophilia A therapy – global progress towards optimal careHaemophilia, 2006
- Home management of haemophiliaHaemophilia, 2004
- Use of implantable venous access devices in children with severe hemophilia: benefits and burden.2004
- Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper.2000